H.C. Wainwright reaffirmed their positive stance on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy rating and a price target of $18.00, representing significant upside potential from the current price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback